BeOne Medicines AG (BEIGF)
| Market Cap | 34.49B +35.4% |
| Revenue (ttm) | 5.70B +29.9% |
| Net Income | 533.73M |
| EPS | 4.52 |
| Shares Out | n/a |
| PE Ratio | 64.62 |
| Forward PE | 43.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 52,500 |
| Open | 22.50 |
| Previous Close | 23.75 |
| Day's Range | 22.50 - 22.50 |
| 52-Week Range | 15.95 - 24.92 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 31, 2026 |
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w... [Read more]
News
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Goldman Sachs 4...
China AI firms Zhipu, MiniMax to join Hong Kong’s Hang Seng Tech Index
Chinese AI firms MiniMax Group and Knowledge Atlas Technology – better known as Zhipu AI – will join the Hang Seng Tech Index next month. Their inclusion follows investor criticism that the city’s pri...
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematol...
BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today launched One Save Changes Everything, a ca...
BeOne Medicines price target raised to $367 from $364 at Leerink
Leerink raised the firm’s price target on BeOne Medicines (ONC) to $367 from $364 and keeps an Outperform rating on the shares. The firm notes the company announced that the…
BeOne Medicines (ONC) Receives FDA Fast-Tracked Approval for Beqalzi
BeOne Medicines (ONC) Receives FDA Fast-Tracked Approval for Beqalzi
BeOne Medicines’ Beqalzi granted accelerated approval by FDA
BeOne Medicines (ONC) announced that the U.S. Food and Drug Administration has granted accelerated approval to Beqalzi, a next-generation BCL2 inhibitor, for the treatment of adult patients with relap...
US FDA approves BeOne's drug for a type of blood cancer
BeOne Medicines said on Wednesday that the U.S. Food and Drug Administration has approved its drug for a type of blood cancer.
BeOne Medicines' BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Admi...
BeOne Medicines’ BEQALZI (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ...
BeOne Medicines price target raised to $395 from $389 at Morgan Stanley
Morgan Stanley raised the firm’s price target on BeOne Medicines (ONC) to $395 from $389 and keeps an Overweight rating on the shares.
BeOne Medicines price target raised to $409 from $405 at Barclays
Barclays raised the firm’s price target on BeOne Medicines (ONC) to $409 from $405 and keeps an Overweight rating on the shares.
BeOne Medicines price target raised to $420 from $410 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on BeOne Medicines (ONC) to $420 from $410 and keeps a Buy rating on the shares after the company reported a
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
Business Wire India Total global revenues of $1.5 billion for the first quarter, an increase of 35% from the prior year Foundational BRUKINSA (zanubrutinib) global revenues of $1.1 billion for…
BeOne Medicines AG Earnings Call Transcript: Q1 2026
Q1 2026 saw 34% revenue growth to $1.5B, led by BRUKINSA's 38% increase and strong global demand. Full-year revenue guidance was raised by $100M, with robust progress in hematology and solid tumor pipelines, and margin expansion driven by improved product mix.
BeOne Medicines AG Earnings release: Q1 2026
BeOne Medicines AG released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
BeOne Medicines AG Quarterly report: Q1 2026
BeOne Medicines AG has published its Q1 2026 quarterly earnings report on May 6, 2026.
BeOne Medicines AG Slides: Q1 2026
BeOne Medicines AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates fr...
BeOne Medicines initiated with an Overweight at Wells Fargo
Wells Fargo analyst Yanan Zhu initiated coverage of BeOne Medicines (ONC) with an Overweight rating and $400 price target The firm believes the company is well positioned in the $12B
BeOne Medicines (ONC) Receives FDA Priority Review for Tevimbra Treatment
BeOne Medicines (ONC) Receives FDA Priority Review for Tevimbra Treatment
BeOne Medicines: FDA grants Priority Review to sBLA for tevimbra/ziihera combo
BeOne Medicines (ONC) announced that the U.S. FDA has granted Priority Review to a supplemental Biologics License Application for tevimbra in combination with ziihera and chemotherapy for the first-li...
U.S. FDA Grants Priority Review to BeOne Medicines' TEVIMBRA in First-Line HER2+ GEA
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration...
BeOne Medicines AG Proxy statement: Proxy filing
BeOne Medicines AG filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
BeOne Medicines AG Proxy statement: Proxy filing
BeOne Medicines AG filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.